SCHEMBL14814909

SCHEMBL14814909

CC(C)(C)OC(=O)N(Nc1nc(-c2ccccc2)cs1)C(=O)OC(C)(C)C

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.51
ALDH1A1 P00352 3/20 0.51
GAA P10253 3/20 0.51
LMNA P02545 3/20 0.51
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
RAB9A P51151 2/20 0.51
KDM4E B2RXH2 2/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
ALOX12 P18054 1/20 0.50
GFER P55789 1/20 0.50
NPC1 O15118 1/20 0.49
CASP3 P42574 1/20 0.49
SENP7 Q9BQF6 1/20 0.49
ADORA3 P0DMS8 2/20 0.49
GSTO1 P78417 2/20 0.48
ELOVL1 Q9BW60 1/20 0.47
CSNK2A1 P68400 1/20 0.47
PARP1 P09874 1/20 0.46
ROCK2 O75116 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14814911 0.83 MAPT (0.47) MAPTALDH1A1GAALMNAMEN1
SCHEMBL14814463 0.79 MAPT (0.66) MAPTALDH1A1GAALMNAMEN1
SCHEMBL14829853 0.77 MAPT (0.51) MAPTALDH1A1GAALMNAMEN1
SCHEMBL14814910 0.76 SMN1; SMN2 (0.46) MAPTALDH1A1LMNAMEN1KMT2A
SCHEMBL23554173 0.75 GSTO1 (0.55) MAPTALDH1A1GAALMNAMEN1
SCHEMBL14827149 0.75 KMT2A (0.55) MAPTALDH1A1LMNAMEN1KMT2A
SCHEMBL21225310 0.74 RAB9A (0.60) MAPTALDH1A1LMNAMEN1KMT2A
SCHEMBL21225318 0.74 MAPT (0.55) MAPTALDH1A1LMNAMEN1KMT2A
SCHEMBL21225316 0.74 MAPT (0.55) MAPTALDH1A1LMNAMEN1KMT2A
SCHEMBL14829852 0.73 MAPT (0.66) MAPTALDH1A1GAALMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130085157-A1 ARYLSUBSTITUTED THIAZOLOTRIAZOLES AND THIAZOLOIMIDAZOLES SMITH EMILIE D (US) 2013-04-04 US disclosed
US-20130085157-A1 ARYLSUBSTITUTED THIAZOLOTRIAZOLES AND THIAZOLOIMIDAZOLES SMITH EMILIE D (US) 2013-04-04 US disclosed
US-20130085157-A1 ARYLSUBSTITUTED THIAZOLOTRIAZOLES AND THIAZOLOIMIDAZOLES SMITH EMILIE D (US) 2013-04-04 US disclosed
WO-2013049585-A1 ARYLSUBSTITUTED THIAZOLOTRIAZOLES AND THIAZOLOIMIDAZOLES HENGRUI (USA), LTD. (US) 2013-04-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130085157-A1 ARYLSUBSTITUTED THIAZOLOTRIAZOLES AND THIAZOLOIMIDAZOLES TGM2, CCT5, TSHR MAPT 1520/4885ALDH1A1 4145/4885GAA 512/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.